<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>ULIPRISTAL - Research Report</title>
    <meta name="description" content="Comprehensive naturopathic research report for ULIPRISTAL">
    <style>

    * {
        box-sizing: border-box;
    }

    body {
        font-family: 'Segoe UI', 'Helvetica Neue', Arial, sans-serif;
        font-size: 16px;
        line-height: 1.6;
        margin: 0;
        padding: 0;
        background-color: #f8f9fa;
        color: #212529;
    }

    .container {
        max-width: 1200px;
        margin: 0 auto;
        padding: 20px;
        background-color: white;
        box-shadow: 0 0 10px rgba(0,0,0,0.1);
    }

    .medication-header {
        background: linear-gradient(135deg, #2c3e50, #003366);
        color: white;
        padding: 30px;
        margin: -20px -20px 30px -20px;
        border-radius: 0 0 10px 10px;
        text-align: center;
        position: relative;
    }

    .medication-header h1 {
        margin: 0 0 15px 0;
        font-size: 2.5em;
        font-weight: 600;
        text-shadow: 0 2px 4px rgba(0,0,0,0.3);
    }

    .status-badge {
        display: inline-block;
        padding: 8px 20px;
        border-radius: 25px;
        font-weight: 600;
        font-size: 0.9em;
        text-transform: uppercase;
        letter-spacing: 1px;
        box-shadow: 0 2px 4px rgba(0,0,0,0.2);
    }

    .status-allowed { background-color: #28a745; color: white; }
    .status-not-allowed { background-color: #dc3545; color: white; }
    .status-modernization { background-color: #fd7e14; color: white; }
    .status-topical { background-color: #20c997; color: white; }
    .status-review { background-color: #ffc107; color: #212529; }
    .status-not-applicable { background-color: #6c757d; color: white; }
    .status-unknown { background-color: #adb5bd; color: white; }

    .natural-connections {
        margin-bottom: 30px;
        padding: 20px;
        background-color: #f8f9fa;
        border-radius: 10px;
        border-left: 4px solid #007bff;
    }

    .natural-connections h2 {
        margin: 0 0 15px 0;
        font-size: 1.4em;
        color: #2c3e50;
    }

    .connection-tags {
        display: flex;
        flex-wrap: wrap;
        gap: 8px;
    }

    .connection-tag {
        display: inline-block;
        padding: 6px 12px;
        border-radius: 15px;
        font-size: 0.85em;
        font-weight: 500;
        color: white;
        white-space: nowrap;
    }

    .tag-direct { background-color: #0d6832; }
    .tag-semi-synthetic { background-color: #198754; }
    .tag-structural { background-color: #0d6efd; }
    .tag-endogenous { background-color: #6610f2; }
    .tag-biosynthetic { background-color: #6f42c1; }
    .tag-pathways { background-color: #0dcaf0; color: #212529; }
    .tag-processes { background-color: #3dd5f3; color: #212529; }

    .report-content {
        line-height: 1.7;
    }

    .report-content h1 {
        color: #2c3e50;
        border-bottom: 3px solid #007bff;
        padding-bottom: 10px;
        margin: 30px 0 20px 0;
    }

    .report-content h2 {
        color: #495057;
        border-bottom: 2px solid #dee2e6;
        padding-bottom: 8px;
        margin: 25px 0 15px 0;
    }

    .report-content h3 {
        color: #6c757d;
        margin: 20px 0 10px 0;
    }

    .report-content p {
        margin-bottom: 15px;
        text-align: justify;
    }

    .checkbox {
        font-weight: bold;
        margin-right: 5px;
    }

    .checkbox.checked { color: #28a745; }
    .checkbox.unchecked { color: #6c757d; }

    .footer {
        margin-top: 40px;
        padding: 20px 0;
        border-top: 1px solid #dee2e6;
        text-align: center;
        color: #6c757d;
        font-size: 0.9em;
    }

    .back-link {
        display: inline-block;
        margin-bottom: 20px;
        padding: 8px 16px;
        background-color: #007bff;
        color: white;
        text-decoration: none;
        border-radius: 5px;
        transition: background-color 0.3s;
    }

    .back-link:hover {
        background-color: #0056b3;
        text-decoration: none;
    }

    @media (max-width: 768px) {
        .container {
            padding: 15px;
            margin: 10px;
        }
        .medication-header {
            margin: -15px -15px 20px -15px;
            padding: 20px;
        }
        .medication-header h1 {
            font-size: 2em;
        }
        .connection-tags {
            justify-content: center;
        }
    }

    @media print {
        .back-link { display: none; }
        .container { box-shadow: none; }
        .medication-header {
            background: #2c3e50 !important;
            -webkit-print-color-adjust: exact;
        }
    }

    </style>
</head>
<body>
    <div class="container">
        <a href="index.html" class="back-link">← Back to Index</a>

        <header class="medication-header">
            <h1>ULIPRISTAL</h1>
            <div class="status-badge status-allowed">
                ALLOWED
            </div>
        </header>

        <section class="natural-connections">
            <h2>Natural Connections</h2>
            <div class="connection-tags">
                <span class="connection-tag tag-semi-synthetic">Semi-Synthetic</span>
<span class="connection-tag tag-structural">Structural Analog</span>
<span class="connection-tag tag-pathways">Works Natural Pathways</span>
<span class="connection-tag tag-processes">Facilitates Natural Processes</span>
            </div>
        </section>

        <main class="report-content">
            <p>Naturopathic Formulary Medication Evaluation Protocol</p>

<p># Objective: Comprehensive assessment of natural derivation and therapeutic alignment For <strong>ULIPRISTAL</strong>: ## <h2>1. NATURAL DERIVATION ASSESSMENT</h2></p>

<p>### <h3>Source Investigation</h3> Ulipristal functions through interaction with endogenous progesterone receptors (PR), acting as both an agonist and antagonist depending on the hormonal environment. Ulipristal acetate functions as a selective progesterone receptor modulator, binding with high affinity to progesterone receptors and exhibiting tissue-selective agonist and antagonist activity. While developed through modern medicinal chemistry, the medication was intentionally crafted to engage these conserved pathways so clinicians can modulate them in a targeted way. ULIPRISTAL works through established physiological pathways to achieve therapeutic effects. ULIPRISTAL is produced through modification of natural compounds, preserving the essential natural framework while enhancing therapeutic properties. Ulipristal acetate is a synthetic selective progesterone receptor modulator (SPRM) that is not directly extracted from natural sources. Additionally, it is structurally derived from 19-norprogesterone, which itself is related to the naturally occurring hormone progesterone. The compound was developed through medicinal chemistry modifications of steroid hormone structures found in nature. There is no documented traditional medicine use of ulipristal specifically, though progesterone-related compounds have been used historically in various forms of traditional women&#x27;s health practices.</p>

<h3>Structural Analysis</h3> Ulipristal acetate shares the core steroid backbone structure characteristic of naturally occurring sex hormones, particularly progesterone. The molecule contains the same four-ring steroid nucleus (cyclopentanoperhydrophenanthrene) found in all natural steroid hormones. Key structural features include modifications at the 11β and 17α positions that distinguish it from natural progesterone while maintaining the fundamental steroid architecture. The compound retains functional groups that allow interaction with steroid hormone receptors, demonstrating clear structural relationship to endogenous compounds.

<h3>Biological Mechanism Evaluation</h3> Ulipristal functions through interaction with endogenous progesterone receptors (PR), acting as both an agonist and antagonist depending on the hormonal environment. It binds to the same progesterone receptors that respond to naturally occurring progesterone, integrating directly into the hypothalamic-pituitary-ovarian axis. The medication works within established endogenous regulatory pathways for reproductive hormone control, affecting ovulation timing and endometrial development through natural receptor mechanisms.

<h3>Natural System Integration</h3> (Expanded Assessment) Ulipristal targets naturally occurring progesterone receptors found throughout the female reproductive system, working within evolutionarily conserved steroid hormone signaling pathways. It modulates the natural menstrual cycle by affecting the timing of luteinizing hormone (LH) surge and ovulation, processes that are fundamental to mammalian reproduction. The medication enables the body&#x27;s natural mechanisms for preventing fertilization or implantation when used as emergency contraception. It works by temporarily disrupting normal hormonal signaling rather than introducing non-endogenous mechanism with natural system compatibility, allowing natural cycles to resume after clearance. The compound facilitates a return to normal physiological function by providing a time-limited intervention in natural reproductive processes.

<h2>2. THERAPEUTIC CONTEXT</h2>

<p>### Mechanism of Action Ulipristal acetate functions as a selective progesterone receptor modulator, binding with high affinity to progesterone receptors and exhibiting tissue-selective agonist and antagonist activity. When used for emergency contraception, it primarily works by delaying or inhibiting ovulation through suppression of the luteinizing hormone surge. The medication also affects endometrial development and may alter cervical mucus consistency. Its mechanism relies on modulation of natural hormonal cascades rather than introducing non-physiological processes.</p>

<h3>Clinical Utility</h3> Primary therapeutic applications include emergency contraception when used within 120 hours of unprotected intercourse, with efficacy declining over time and remaining superior to levonorgestrel-based emergency contraceptives at later time points. Ulipristal acetate (as ellaOne) demonstrates approximately 98-99% efficacy when used within 72 hours, maintaining effectiveness better than alternatives at 72-120 hours post-coitus. The safety profile shows minimal serious adverse effects, with nausea, headache, and menstrual irregularities being the most common side effects. This represents temporary, targeted intervention rather than long-term medication use.

<h3>Integration Potential</h3> Ulipristal demonstrates compatibility with naturopathic approaches as a temporary intervention that works within natural hormonal systems. It can be integrated into comprehensive reproductive health planning alongside lifestyle, nutritional, and botanical approaches to reproductive wellness. The medication creates a therapeutic window for implementing natural fertility awareness methods and cycle regulation strategies. Practitioner education would focus on understanding steroid hormone physiology and the medication&#x27;s specific receptor interactions.

<h2>3. REGULATORY AND PRECEDENT CONTEXT</h2>

<p>### Current Status Ulipristal acetate is FDA-approved for emergency contraception under the brand name ella, requiring prescription access in the United States. It received FDA approval in August 2010 following extensive clinical trials. The European Medicines Agency approved ulipristal acetate for emergency contraception, and it is available in many countries worldwide. The medication is classified as a prescription-only medicine in most jurisdictions due to the need for appropriate timing and counseling regarding use.</p>

<h3>Comparable Medications</h3> Other steroid hormone-related compounds are included in various naturopathic formularies, including bioidentical hormones like progesterone, estradiol, and testosterone. Levonorgestrel, another synthetic hormone used for emergency contraception, provides precedent for inclusion of hormone-modulating medications. The acceptance of other selective receptor modulators and hormone replacement therapies in integrative medicine practice supports consideration of similar compounds that work through natural receptor systems.

<h3>Formulary Precedent Analysis</h3>

<p>This medication aligns with established formulary principles that recognize both naturally-derived and laboratory-produced compounds when they demonstrate therapeutic value and integration with physiological systems. Similar to synthetic hormones already included in the formulary (ethinyl estradiol, levothyroxine), this medication demonstrates that production method works to preclude formulary inclusion when the therapeutic mechanism aligns with natural physiological processes. The precedent established by medications like tretinoin, sucralfate, and cholestyramine supports inclusion of compounds that work through natural pathways regardless of their origin.</p>

<h2>4. COMPREHENSIVE ASSESSMENT</h2> <strong>ULIPRISTAL</strong> <p><strong><strong>Evidence Categories Present:</strong></strong></p>

<ul>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Direct natural source</li>

<li><span class="checkbox checked">✓</span> Semi-synthetic from natural precursor</li>

<li><span class="checkbox checked">✓</span> Structural analog of natural compound</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Endogenous compound or replacement</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Biosynthetic/fermentation product</li>

<li><span class="checkbox checked">✓</span> Works through natural pathways/receptors</li>

<li><span class="checkbox checked">✓</span> Facilitates natural physiological processes</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> No identified natural connection</li>

</ul><p><strong>Natural Derivation Assessment:</strong></p>

<p>Ulipristal acetate demonstrates clear structural derivation from naturally occurring steroid hormones, specifically maintaining the four-ring steroid nucleus characteristic of progesterone and related reproductive hormones. While synthetically manufactured, the compound represents a modified version of natural steroid architecture rather than a specifically designed structure.</p><p><strong>Structural/Functional Relationships:</strong></p>

<p>The medication shares the core cyclopentanoperhydrophenanthrene ring system found in all naturally occurring steroid hormones. Functional groups and stereochemistry allow binding to the same progesterone receptors that respond to endogenous progesterone, demonstrating preserved natural recognition patterns with synthetic modifications.</p><p><strong>Biological Integration:</strong></p>

<p>Ulipristal integrates directly into the hypothalamic-pituitary-ovarian axis through progesterone receptor binding, modulating natural hormonal cascades involved in ovulation and menstrual cycle regulation. The compound works within established endocrine feedback loops rather than creating novel biological pathways.</p><p><strong>Natural System Interface:</strong></p>

<p>The medication enables temporary modulation of natural reproductive timing mechanisms, allowing normal physiological processes to resume after clearance. It works by affecting the timing of natural events (ovulation, endometrial changes) rather than permanently altering reproductive function, facilitating return to normal cyclical patterns.</p><p><strong>Safety and Therapeutic Profile:</strong></p>

<p>Clinical studies demonstrate favorable safety profile with primarily mild, transient side effects including nausea, headache, and temporary menstrual irregularities. The medication offers a less invasive alternative to other emergency contraceptive methods and requires only single-dose administration. Contraindications include pregnancy and severe hepatic impairment.</p><p><strong>Summary of Findings:</strong></p>

<p>ULIPRISTAL demonstrates significant therapeutic value through integration with natural physiological systems. The medication&#x27;s hormonal effects work through established biological pathways, supporting the body&#x27;s inherent healing processes. Evidence supports inclusion in the naturopathic formulary based on demonstrated therapeutic efficacy, safety profile, and alignment with principles of supporting natural healing. The medication fills a critical therapeutic need while maintaining compatibility with naturopathic treatment approaches.</p><p><strong><strong>Relevant Citations:</strong></strong></p>

<ol>

<li>DrugBank Online. &quot;Ulipristal acetate.&quot; DrugBank Accession Number DB08867. University of Alberta, updated 2024. Available at: https://go.drugbank.com/drugs/DB08867 2. Food and Drug Administration. &quot;ella (ulipristal acetate) tablet, for oral use. Prescribing Information.&quot; FDA Application Number NDA 022474. Initial approval August 2010, revised 2019.</li>

<li>Glasier AF, Cameron ST, Fine PM, Logan SJ, Casale W, Van Horn J, Sogor L, Blithe DL, Scherrer B, Mathe H, Jaspart A, Ulmann A, Gainer E. &quot;Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis.&quot; Lancet. 2010 Feb 13;375(9714):555-62.</li>

<li>PubChem. &quot;Ulipristal acetate.&quot; PubChem CID 130904. National Center for Biotechnology Information, National Library of Medicine.</li>

<li>Brache V, Cochon L, Jesam C, Maldonado R, Salvatierra AM, Levy DP, Gainer E, Croxatto HB. &quot;Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture.&quot; Human Reproduction. 2010 Sep;25(9):2256-63.</li>

<li>Stratton P, Levens ED, Hartog B, Piquion J, Wei Q, Merino M, Nieman LK. &quot;Endometrial effects of a single early luteal dose of the selective progesterone receptor modulator CDB-2914.&quot; Fertility and Sterility. 2010 Jun;94(6):2761-6.</li>

<li>Fine P, Mathé H, Ginde S, Cullins V, Morfesis J, Gainer E. &quot;Ulipristal acetate taken 48-120 hours after intercourse for emergency contraception.&quot; Obstetrics &amp; Gynecology. 2010 Aug;116(2 Pt 1):257-63.</li>

</ol>
        </main>

        <footer class="footer">
            <p>Generated on September 24, 2025 at 07:19 AM</p>
        </footer>
    </div>
</body>
</html>